Retail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

By Amina Niasse NEW YORK (Reuters) -Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

Hims & Hers Health, Inc. navigates strong growth and partnerships despite rising competitive risks. Click here to read an ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO) to distribute branded Wegovy at ...

Hims to cut 4% of workforce amid ban on weight ... cancer risks Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related cancers ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

It's plainly apparent that Novo Nordisk has had May 22 circled its calendar since February, when the FDA began the countdown ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...